Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Kibow Biotech
NEWTOWN SQUARE, Pa., May 7, 2014 /PRNewswire/ -- Kibow Biotech is delighted to be announced a winner of this year's BIO International Convention (June 23 – 26), Buzz of BIO Contest. The Pennsylvania based company is one of the four winners in this year's contest recognizing the most innovative companies in the biotech sector. Kibow Biotech won in the category of "Pipelines of Promise". Kibow will join three other winners and more than 160 industry leaders delivering 15 minute company presentation at the BIO Business Forum. The full press release can be found at:
This is the first time that a biotechnology company specializing exclusively in dietary supplement products is being recognized as one of the winners in the "Buzz of BIO Awards". Dr. Natarajan Ranganathan – the co-founder and chief R&D scientist says that "the decade of research efforts on the concept of balancing the Gut Microbiome with probiotics (beneficial health impacting microbes) is finally gaining more recognition". He also added that a scientific basis and rationale for "a shift from Human Genome to Gut Microbiome" has been established only recently, and the process of using it to address various healthcare problems is just beginning both in the field of drugs and as well in the rapidly growing dietary supplement uses. (Ref: Health in a Pill – Building the case of Supplements – the cover story April 21, 2014 – Chemical and Engineering News).
The company's recognition and award is a cumulative impact of its earlier selection for a poster presentation as Emerging Biotech Company at the 2007 BIO-Boston meeting, its novel concept, and its pharmaceutical-like validation of the product based on "enteric uremic toxin reduction technology" (Enteric Dialysis®). This dietary supplement product, in combination with the standard-of-care treatment for primary diseases such as diabetes, hypertension and other related conditions, may help delay the progression to dialysis status. Subject to additional clinical trials and its validation, the product also possesses an excellent potential to reduce the frequency or duration of dialysis, affording better outcomes and saving billions of healthcare dollars worldwide. Kibow is looking for partnering with a major INTERNATIONAL pharmaceutical or Biotech Company to advance its presence worldwide.
About Kibow Biotech: Founded in Oct 1, 1997 in Philadelphia, Kibow Biotech specializes in research, development and commercialization of probiotic dietary supplements adhering to US FDA and FTC regulations. The Company's primary mission is to offer affordable, readily available and easily administered dietary supplements in support of kidney health and other healthcare applications. The Company's flagship product, Renadyl™, is currently marketed in the U.S. and Canada, and will progressively be made available worldwide, according to individual countries' governmental rules and regulatory authorities.
About Enteric Uremic Toxin Reduction Technology:
Kibow's novel "enteric uremic toxin reduction technology" addresses the accumulation of various uremic toxins which diffuse into the bowel as a consequence of failing kidney function. The Company's patented and proprietary dietary supplements, Renadyl™ (for humans) and Azodyl® (veterinary formulation) consist of a combination of three specific probiotic microbial strains. The results of various clinical trials, including the latest conducted in 2012, have provided encouraging preliminary evidence that the Company's technology could be effective when the product formulation is taken regularly according to medical directives and in a context of standard care as dictated by individual conditions.
Forward-looking statements: This press release contains forward-looking statements that reflect management's current views of future events, including the current classification of the dietary supplement formulation, Renadyl™, for kidney health in the USA and the possibility of its approval as a drug or food supplement in some other countries according to respective governmental authorities. Kibow is not a pharmaceutical company. Kibow products are not drugs and may not be considered as a treatment or a prevention product or therapy. The dietary supplement formulation of Renadyl™ will not cure, prevent or mitigate any disease. Other factors that could cause or contribute to differences in actual results include, but are not limited to, risks associated with any future clinical trials of product candidates, the possibility that testing may reveal to be undesirable and unintended side effects or other characteristics that may prevent or limit the commercial use of proposed products; whether the cash resources of the Company will be sufficient to fund operations as planned; reliance on key employees, especially senior management; the uncertainty of the Company's future access to capital; the risk that the Company may not secure or maintain relationships with collaborators; and the Company's dependence on intellectual property. The Company expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.
KIBOW BIOTECH INC
610-353-5130 ext. 225
©2012 PR Newswire. All Rights Reserved.